Evaluation and management of recurrent pericarditis in special populations: A contemporary review

Abstract

About 15 - 30% of patients develop recurrent episodes of pericarditis following an acute pericarditis attack. In developed countries, most cases of pericarditis are of idiopathic etiology. First-line therapy typically includes non-steroidal antiinflammatory drugs (NSAIDs) and colchicine, with corticosteroids being the traditional second-line agents. Anti-interleukin-1 (IL-1) agents are a novel treatment option increasingly utilized due to their high efficacy as an alternative second-line therapy or for resistant cases, while pericardiectomy remains the last resort. Special populations with recurrent pericarditis (RP), including patients at the extremes of age or during pregnancy, have been understudied. In some cases, pericarditis may develop secondary to infections (including viral infections, such as coronavirus disease 2019, bacterial infections, such as tuberculosis, and fungal infections), autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, and inflammatory bowel disease), post-cardiac injury syndromes, cancer, and other rare conditions. Non-idiopathic etiologies are associated with a higher risk of RP, chronic constrictive pericarditis, and cardiac tamponade. The general treatment algorithm may not be applicable to these special populations due to patient-related or etiological factors. For example, NSAIDs or corticosteroids are often contraindicated in older patients due to comorbidities. Bacterial or fungal purulent pericarditis requires aggressive treatment of infection followed by pericardial fluid drainage, with corticosteroids and anti-IL-1 agents contraindicated in these cases. Therefore, management often requires a multidisciplinary approach and must take place at a specialized pericardial center to optimize patient outcomes. In this review, we present current evidence on the evaluation and management of RP in the aforementioned special populations.

Keywords

Pericarditis / Recurrent pericarditis / Echocardiography / Cardiac magnetic resonance / Special populations / Anti-inflammatories / Anti-interleukin-1 agents

Acknowledgments

None.

Funding

None.

Conflict of interest

Allan L. Klein has received research grants from Kiniksa Pharmaceuticals and Cardiol Therapeutics and serves on the Advisory Boards of Kiniksa Pharmaceuticals, Cardiol Therapeutics, and Pfizer. Separately, the other authors declare no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

Author contributions

Conceptualization: Harsha Sanaka, Tom Kai Ming Wang

Writing - original draft: Harsha Sanaka, Elio Haroun, Karl Abou Zeid, Aro Daniela Arockiam

Writing - review & editing: Harsha Sanaka, Tom Kai Ming Wang, Allan L. Klein

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data

Not applicable.

References

[1] Klein A, Cremer P, Kontzias A, et al. US database study of clinical burden and unmet need in recurrent pericarditis. J Am Heart Assoc. 2021; 10(15):e018950. doi: 10.1161/JAHA.120.018950

[2] Lazarou E, Tsioufis P, Vlachopoulos C, Tsioufis C, Lazaros G. Acute pericarditis: Update. Curr Cardiol Rep. 2022; 24(8):905-913. doi: 10.1007/s11886-022-01710-8

[3] Klein AL, Wang TKM, Cremer PC , et al. Pericardial diseases: International position statement on new concepts and advances in multimodality cardiac imaging. JACC Cardiovasc Imaging. 2024; 17(8):937-988. doi: 10.1016/j.jcmg.2024.04.010

[4] Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015; 36(42):2921-2964. doi: 10.1093/eurheartj/ehv318

[5] Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues in the management of pericardial diseases. Circulation. 2010; 121(7):916-928. doi: 10.1161/CIRCULATIONAHA.108.844753

[6] Sanaka H, Haroun E, Arockiam AD, Dong T, Klein A, Wang TKM. Advances in the multimodality imaging and management of recurrent pericarditis: A contemporary review. Curr Cardiol Rep. 2024;26:1359-1375. doi: 10.1007/s11886-024-02133-3

[7] Kumar S. Furqan M, Kafil T, et al. The Paradigm Shift in the Management of Recurrent Pericarditis. American College of Cardiology; 2023. Available from: https://www.acc.org/latest-in-cardiology/articles/2022/12/19/14/52/the-paradigm-shift-in-the-management-of-recurrentpericarditisLast accessed on 2024 Dec 29].

[8] Klein AL, Abbara S, Agler DA, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: Endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2013; 26(9):965-1012.e15. doi: 10.1016/j.echo.2013.06.023

[9] Wang TKM, Ayoub C, Chetrit M, et al. Cardiac magnetic resonance imaging techniques and applications for pericardial diseases. Circ Cardiovasc Imaging. 2022; 15(7):e014283. doi: 10.1161/CIRCIMAGING.122.014283

[10] Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson. 2020; 22(1):17. doi: 10.1186/s12968-020-00607-1

[11] Taylor AM, Dymarkowski S, Verbeken EK, Bogaert J. Detection of pericardial inflammation with lateenhancement cardiac magnetic resonance imaging: Initial results. Eur Radiol. 2006; 16(3):569-574. doi: 10.1007/s00330-005-0025-0

[12] Deftereos SG, Beerkens FJ, Shah B, et al. Colchicine in cardiovascular disease: In-depth review. Circulation. 2022; 145(1):61-78. doi: 10.1161/CIRCULATIONAHA.121.056171

[13] Puckett Y, Gabbar A, Bokhari AA. Prednisone. In: StatPearls. Treasure Island, FL: StatPearls; 2023.

[14] Grant JK, Shah NP. The impact of physical activity on pericarditis. Curr Cardiol Rep. 2021; 23(10):150. doi: 10.1007/s11886-021-01578-0

[15] Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: The AIRTRIP randomized clinical trial. JAMA. 2016; 316(18):1906-1912. doi: 10.1001/jama.2016.15826

[16] Klein AL, Imazio M, Cremer P , et al. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med. 2021; 384(1):31-41. doi: 10.1056/NEJMoa2027892

[17] Myachikova VY, Maslyanskiy AL, Moiseeva OM, et al. Treatment of idiopathic recurrent pericarditis with goflikicept: Phase II/III study results. J Am Coll Cardiol. 2023; 82(1):30-40. doi: 10.1016/j.jacc.2023.04.046

[18] Correia ETO, Dos Santos Barbetta LM, et al. Anakinra in recurrent pericarditis: Current evidence on clinical use, effectiveness, and safety. J Cardiovasc Pharmacol. 2020; 76(1):42-49. doi: 10.1097/FJC.0000000000000839

[19] Wang TKM, Klein AL. Rilonacept (Interleukin-1 Inhibition) for the treatment of pericarditis. Curr Cardiol Rep. 2022; 24(1):23-30. doi: 10.1007/s11886-021-01621-0

[20] Dong T, Klein AL, Wang TKM. Paradigm shift in diagnosis and targeted therapy in recurrent pericarditis. Curr Cardiol Rep. 2023; 25(9):993-1000. doi: 10.1007/s11886-023-01912-8

[21] Cardiol Therapeutics. Cardiol Therapuetics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis. Canada: Cardiol Therapeutics; 2024. Available from: https://www.cardiolrx.com/cardioltherapeutics-granted-orphan-drug-designation-for-itslead-drug-candidate-for-the-treatment-of-pericarditis/Last accessed on 2024 Dec 29].

[22] Drossner DM, Hirsh DA, Sturm JJ, et al. Cardiac disease in pediatric patients presenting to a pediatric ED with chest pain. Am J Emerg Med. 2011; 29(6):632-638. doi: 10.1016/j.ajem.2010.01.011

[23] Ratnapalan S, Brown K, Benson L. Children presenting with acute pericarditis to the emergency department. Pediatr Emerg Care. 2011; 27(7):581-585. doi: 10.1097/PEC.0b013e31822251ba

[24] Krasic S, Prijic S, Ninic S, et al. Predictive factors of recurrence after pediatric acute pericarditis. J Pediatr (Rio J). 2021; 97(3):335-341. doi: 10.1016/j.jped.2020.06.007

[25] Tombetti E, Giani T, Brucato A, et al. Recurrent pericarditis in children and adolescents. Front Pediatr. 2019;7:419. doi: 10.3389/fped.2019.00419

[26] Imazio M, Pedrotti P, Quattrocchi G, et al. Multimodality imaging of pericardial diseases. J Cardiovasc Med (Hagerstown). 2016; 17(11):774-782. doi: 10.2459/JCM.0000000000000427

[27] Imazio M, Brucato A, Pluymaekers N, et al. Recurrent pericarditis in children and adolescents: A multicentre cohort study. J Cardiovasc Med (Hagerstown). 2016; 17(9):707-712. doi: 10.2459/JCM.0000000000000300

[28] Schror K. Aspirin and reye syndrome: A review of the evidence. Paediatr Drugs. 2007; 9(3):195-204. doi: 10.2165/00148581-200709030-00008

[29] Drozdowicz LB, Bostwick JM. Psychiatric adverse effects of pediatric corticosteroid use. Mayo Clin Proc. 2014; 89(6):817-834. doi: 10.1016/j.mayocp.2014.01.010

[30] Caorsi R, Insalaco A, Bovis F, et al. Pediatric recurrent pericarditis: Appropriateness of the standard of care and response to IL-1 blockade. J Pediatr. 2023; 256:18-26.e8. doi: 10.1016/j.jpeds.2022.11.034

[31] Finetti M, Insalaco A, Cantarini L, et al. Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. J Pediatr. 2014; 164(6):1425-1431.e1. doi: 10.1016/j.jpeds.2014.01.065

[32] Bizzi E, Cavaleri F, Mascolo R, et al. Recurrent pericarditis in older adults: Clinical and laboratory features and outcome. J Am Geriatr Soc. 2024; 72(11):3467-3475. doi: 10.1111/jgs.19150

[33] Massaro MG, Gallo A, Montalto M, Manna R, Gemelli- Against-Pericarditis Group. Treatment of recurrent pericarditis in elderly. Eur J Intern Med. 2023; 112:133-135. doi: 10.1016/j.ejim.2023.02.007

[34] Serati L, Carnovale C, Maestroni S, et al. Management of acute and recurrent pericarditis in pregnancy. Panminerva Med. 2021; 63(3):276-287. doi: 10.23736/S0031-0808.21.04198-7

[35] Prokšelj K, Brida M. Cardiovascular imaging in pregnancy. Int J Cardiol Congen Heart Dis. 2021;5:100235. doi: 10.1016/j.ijcchd.2021.100235

[36] Brucato A, Pluymaekers N, Tombetti E, et al. Management of idiopathic recurrent pericarditis during pregnancy. Int J Cardiol. 2019; 282:60-65. doi: 10.1016/j.ijcard.2019.02.003

[37] Lotan D, Wasserstrum Y, Itelman E, et al. Management and outcome of acute and recurrent pericarditis during pregnancy. Eur Heart J. 2020; 41(Suppl 2):2157. doi: 10.1093/ehjci/ehaa946.2157

[38] Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol (Hoboken). 2020; 72(4):529-556. doi: 10.1002/art.41191

[39] Youngstein T, Hoffmann P, Gul A, et al. International multicentre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology (Oxford). 2017; 56(12):2102-2108. doi: 10.1093/rheumatology/kex305

[40] U.S. Food and Drug Administration. Arcalyst (Rilonacept) Label. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfmLast accessed on 2024 Dec 29].

[41] Buckley BJR, Harrison SL, Fazio-Eynullayeva E, Underhill P, Lane DA, Lip GYH. Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. Eur J Clin Invest. 2021; 51(11):e13679. doi: 10.1111/eci.13679

[42] Diaz-Arocutipa C, Saucedo-Chinchay J, Imazio M. Pericarditis in patients with COVID-19: A systematic review. J Cardiovasc Med (Hagerstown). 2021; 22(9):693-700. doi: 10.2459/JCM.0000000000001202

[43] Howick JFt, Saric P, Elwazir M, et al. A pragmatic study of cardiovascular disease during long-term COVID-19. Am J Med. 2025; 138:532-540.e1 doi: 10.1016/j.amjmed.2024.03.011

[44] Chen C, Chen C, Cao L, Fang J, Xiao J. Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study. Int Immunopharmacol. 2024;133:112022. doi: 10.1016/j.intimp.2024.112022

[45] Khasnavis S, Habib M, Kaawar F, et al. New perspectives on long COVID syndrome: The development of unusually delayed and recurring pericarditis after a primary SARSCoV- 2 infection. Cureus. 2022; 14(6):e25559. doi: 10.7759/cureus.25559

[46] Brucato A, Trotta L, Arad M, et al. Absence of pericarditis recurrence in rilonacept-treated patients with COVID-19 and SARS-CoV-2 vaccination: Results from the RHAPSODY long-term extension. CJC Open. 2024; 6(6):805-810. doi: 10.1016/j.cjco.2024.02.002

[47] Collini V, Imazio M, De Biasio M, Sinagra G. Coronavirus disease 2019 vaccination-related pericarditis: A single tertiary-center experience. J Cardiovasc Med (Hagerstown). 2022; 23(12):779-783. doi: 10.2459/JCM.0000000000001365

[48] Conte C, Princi G, D’Amario D, Sanna T, Pedicino D, Liuzzo G. Incessant pericarditis following the second dose of SARS-CoV-2 mRNA vaccine successfully treated with anakinra: A case report. Eur Heart J Case Rep. 2022; 6(9):ytac357. doi: 10.1093/ehjcr/ytac357

[49] Hay MB, Muthalaly RG, Tan S, et al. Incessant myopericarditis after mRNA vaccination requiring IL-1 receptor antagonist therapy and pericardiectomy: Case report. Eur Heart J Case Rep. 2023; 7(9):ytad429. doi: 10.1093/ehjcr/ytad429

[50] Lopez-Lopez JP, Posada-Martinez EL, Saldarriaga C, et al. Tuberculosis and the heart. J Am Heart Assoc. 2021; 10(7):e019435. doi: 10.1161/JAHA.120.019435

[51] Isiguzo G, Du Bruyn E, Howlett P, Ntsekhe M. Diagnosis and management of tuberculous pericarditis: What is new? Curr Cardiol Rep. 2020; 22(1):2. doi: 10.1007/s11886-020-1254-1

[52] Latifi Y, Gugelmann R, Rigger J , et al. Effusive-constrictive pericarditis due to immune reconstitution inflammatory syndrome following tuberculous pericarditis. CASE (Phila). 2021; 5(1):67-72. doi: 10.1016/j.case.2020.10.012

[53] Wiysonge CS, Ntsekhe M, Thabane L, et al. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2017; 9(9):CD000526. doi: 10.1002/14651858.CD000526.pub2

[54] Zayas R, Anguita M, Torres F, et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. Am J Cardiol. 1995; 75(5):378-382. doi: 10.1016/s0002-9149(99)80558-x

[55] Adamichou C, Bertsias G. Flares in systemic lupus erythematosus: Diagnosis, risk factors and preventive strategies. Mediterr J Rheumatol. 2017; 28(1):4-12. doi: 10.31138/mjr.28.1.4

[56] Pan SY, Tian HM, Zhu Y, et al. Cardiac damage in autoimmune diseases: Target organ involvement that cannot be ignored. Front Immunol. 2022;13:1056400. doi: 10.3389/fimmu.2022.1056400

[57] Goldar G, Garraud C, Sifuentes AA, Wassif H, Jain V, Klein AL. Autoimmune pericarditis: Multimodality imaging. Curr Cardiol Rep. 2022; 24(11):1633-1645. doi: 10.1007/s11886-022-01785-3

[58] Bhalla JS, Saraswati U, Rosenzveig A, Syed A, Majid M, Klein A. Abstract 4138125: Interleukin-1 antagonists in the management of recurrent pericarditis due to autoimmune diseases: Beyond AIRTRIP and RHAPSODY. Circulation. 2024; 150(Suppl 1):A4138125. doi: 10.1161/circ.150.suppl_1.4138125

[59] Malik J, Zaidi SMJ, Rana AS, Haider A, Tahir S. Post-cardiac injury syndrome: An evidence-based approach to diagnosis and treatment. Am Heart J Plus. 2021;12:100068. doi: 10.1016/j.ahjo.2021.100068

[60] Sasse T, Eriksson U. Post-cardiac injury syndrome: Aetiology, diagnosis, and treatment. e-J Cardiol Pract. 2017;15:21-31.

[61] Imazio M, Brucato A, Markel G, et al. Meta-analysis of randomized trials focusing on prevention of the postpericardiotomy syndrome. Am J Cardiol. 2011; 108(4):575-579. doi: 10.1016/j.amjcard.2011.03.087

[62] Bunge JJ, van Osch D, Dieleman JM, et al. Dexamethasone for the prevention of postpericardiotomy syndrome: A dexamethasone for cardiac surgery substudy. Am Heart J. 2014; 168(1):126-31.e1. doi: 10.1016/j.ahj.2014.03.017

[63] Imazio M, Andreis A, De Ferrari GM, et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. Eur J Prev Cardiol. 2020; 27(9):956-964. doi: 10.1177/2047487319879534

[64] Lorenzo-Esteller L, Ramos-Polo R, Pons Riverola A, et al. Pericardial disease in patients with cancer: Clinical insights on diagnosis and treatment. Cancers (Basel). 2024; 16(20):3466. doi: 10.3390/cancers16203466

[65] Ghosh AK, Crake T, Manisty C, Westwood M. Pericardial disease in cancer patients. Curr Treat Options Cardiovasc Med. 2018; 20(7):60. doi: 10.1007/s11936-018-0654-7

[66] Chahine J, Shekhar S, Mahalwar G, Imazio M, Collier P, Klein A. Pericardial involvement in cancer. Am J Cardiol. 2021; 145:151-159. doi: 10.1016/j.amjcard.2020.12.092

[67] Cozma A, Sporis ND, Lazar AL , et al. Cardiac toxicity associated with immune checkpoint inhibitors: A systematic review. Int J Mol Sci. 2022; 23(18):10948. doi: 10.3390/ijms231810948

[68] Chiabrando JG, Bonaventura A, Vecchie A, et al. Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol. 2020; 75(1):76-92. doi: 10.1016/j.jacc.2019.11.021

[69] Chugh S, Singh J, Kichloo A, Gupta S, Katchi T, Solanki S. Uremic-and dialysis-associated pericarditis. Cardiol Rev. 2021; 29(6):310-313. doi: 10.1097/crd.0000000000000381

[70] Alpert MA, Ravenscraft MD. Pericardial involvement in end-stage renal disease. Am J Med Sci. 2003; 325(4):228-236. doi: 10.1097/00000441-200304000-00009

[71] Lundin AP. Recurrent uremic pericarditis: A mark of inadequate dialysis. Semin Dial. 1990; 3(1):5-7. doi: 10.1111/j.1525-139X.1990.tb00003.x

[72] Wang SC, Pashkovetsky E, Conti D, et al. Pericardial effusion after renal transplantation: Timing and clinical characteristics. Transplant Proc. 2021; 53(5):1606-1610. doi: 10.1016/j.transproceed.2021.03.021

[73] Rutsky EA, Rostand SG. Treatment of uremic pericarditis and pericardial effusion. Am J Kidney Dis. 1987; 10(1):2-8. doi: 10.1016/s0272-6386(87)80003-3

[74] Badwan O, Skoza W, Braghieri L, Persits I, Klein AL. When should pharmacologic therapies be used for uremic pericarditis? Cleve Clin J Med. 2023; 90(9):549-554. doi: 10.3949/ccjm.90a.23003

[75] Ridker PM, MacFadyen JG, Glynn RJ, et al. Inhibition of interleukin-1beta by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol. 2018; 71(21):2405-2414. doi: 10.1016/j.jacc.2018.03.490

[76] Alušík Š, Paluch Z. Drug-induced pericarditis. Coret Vasa. 2022; 64(6):637-643.

[77] Johal HK, Barrera A. Clozapine-induced pericarditis: An ethical dilemma. BMJ Case Rep. 2019; 12(6):e229872. doi: 10.1136/bcr-2019-229872

[78] Vijayanarayanan A, Menon MP. Cholesterol pericarditis. N Engl J Med. 2022; 387(11):1021. doi: 10.1056/NEJMicm2118193

[79] Khawaja T, Feroze R, Hoit BD. Cholesterol Pericarditis. JACC Case Rep. 2022; 4(13):808-813. doi: 10.1016/j.jaccas.2022.04.001

[80] Ferreira dos Santos L, Moreira D, Ribeiro P, et al. [Purulent pericarditis: A rare diagnosis]. Pericardite purulenta: Um diagnostico raro. Rev Port Cardiol. 2013; 32(9):721-727. doi: 10.1016/j.repc.2013.07.003